隶属于 torrent investments pvt ltd.
Indian multinational pharmaceutical company headquartered in Ahmedabad, manufacturing generic drugs, vaccines and diagnostics across more than 40 countries with over 2,000 product registrations globally.
相关临床试验
107
15 进行中
药物批准
175
批准总数
监管机构
4
监管机构数
成立时间
1959
已完成
87
81.3%
尚未招募
15
14.0%
招募中
1
0.9%
Unknown
1
0.9%
撤回
1
0.9%
- Xeris Biopharma filed a patent infringement lawsuit against Torrent Pharmaceuticals and Somerset Therapeutics to protect its drug Recorlev from unauthorized generic versions. - The company maintains intellectual property protection through March 2040 and Orphan Drug Exclusivity until December 2028 for Recorlev. - Xeris shares fell 10.83% to $6.01 following the lawsuit announcement, despite the stock gaining 61.30% over the past year. - Analysts maintain a Buy rating with an average price target of $11.03, expecting earnings of 4 cents per share and revenue of $84.17 million for the upcoming report.
- Apozeal Pharmaceuticals will invest $4.1 million to expand its drug manufacturing operations in Bucks County, Pennsylvania, with $1.1 million in state support. - The expansion will create 70 new jobs and retain 22 existing positions over three years while adding new production lines to manufacture seven additional FDA-approved generic drugs. - The company currently holds 11 FDA-approved Abbreviated New Drug Applications and aims to produce 100% of its products domestically in the United States. - Pennsylvania's life sciences sector employs over 100,000 people across nearly 3,100 companies and is expected to create 6,500 new jobs over the next decade.
- Torrent Pharmaceuticals is conducting Phase 3 clinical trials for oral semaglutide and has partnered for injectable versions, positioning itself for launch within 1-2 years following Novo Nordisk's patent expiry. - The company plans to manufacture the active pharmaceutical ingredient in-house at its Gujarat facility while potentially outsourcing fill-finish operations to optimize production costs. - Torrent's entry into the semaglutide market could address unmet demand in India's expanding obesity and diabetes segment, where GLP-1 drugs are gaining traction among clinicians and patients. - The strategic move represents a significant addition to Torrent's chronic medicine portfolio as generic drugmakers prepare for the high-stakes market opportunity post-patent expiry.
- The National Pharmaceutical Pricing Authority (NPPA) has notified retail prices for 71 pharmaceutical formulations under the Drugs Prices Control Order (DPCO) 2013 to improve drug accessibility and affordability across India. - Key cancer treatment trastuzumab for injection (375 mg) has been priced at ₹11,966.64 per vial by Reliance Life Sciences, while various antibiotic combinations range from ₹447 to ₹1,036.60. - The pricing notification includes 25 anti-diabetes formulations containing empagliflozin combinations and other diabetes medications with sitagliptin as components. - Manufacturers are required to display price lists prominently at retail locations and online platforms to enable patients to verify compliance with NPPA-fixed prices.
- Biocon Ltd. is seeking regulatory approval for generic versions of Novo Nordisk's Ozempic and Wegovy, targeting Canada as its first major market entry by 2026. - The Indian pharmaceutical company aims to capitalize on semaglutide patent expirations beginning early next year in Canada and April 2025 in India. - Biocon expects limited price erosion of approximately 20% for generic Wegovy in India, significantly less than the typical 90% reduction seen with other blockbuster drugs. - The company leverages its insulin manufacturing expertise to compete in the crowded generic obesity drug market against rivals including Sandoz, Teva, and local Indian competitors.
- Several Indian pharmaceutical companies are preparing to launch generic versions of Empagliflozin following Boehringer Ingelheim's patent expiry on March 11, potentially transforming diabetes treatment accessibility. - Mankind Pharma plans to offer the diabetes medication at approximately Rs 6 per tablet, a 90% reduction from the innovator's price of Rs 60, with most generic versions expected to cost between Rs 9-14 per tablet. - The affordable generics will significantly reduce therapy costs for India's 10.1 crore diabetic patients, most of whom pay out-of-pocket, while still providing benefits for heart failure and chronic kidney disease management.
